Zbigniev Balion
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Zbigniev Balion has a total of 56 co-authors. Here are the top co-authors by number of shared publications:
- Aistė Jekabsone
Preclinical Research Laboratory for Medicinal Products, Institute of Cardiology, Lithuanian University of Health Sciences, Kaunas, Lithuania
3 shared publications - Edgaras Stankevičius
Preclinical Research Laboratory for Medicinal Products, Institute of Cardiology, Lithuanian University of Health Sciences, 50162 Kaunas, Lithuania
3 shared publications - Agilė Tunaitytė
Preclinical Research Laboratory for Medicinal Products, Institute of Cardiology, Lithuanian University of Health Sciences, 50162 Kaunas, Lithuania
2 shared publications - Augusta Volkevičiūtė
Preclinical Research Laboratory for Medicinal Products, Institute of Cardiology, Lithuanian University of Health Sciences, 50162 Kaunas, Lithuania
2 shared publications - Deimantė Narauskaitė
Preclinical Research Laboratory for Medicinal Products, Institute of Cardiology, Lithuanian University of Health Sciences, 50162 Kaunas, Lithuania
2 shared publications - Dovydas Gečys
Institute of Cardiology, Lithuanian University of Health Sciences, Kaunas, Lithuania, Lithuania
2 shared publications
Latest Publications
- Open Access
- 13 November 2026
- Published by MDPI AG in Current Issues in Molecular Biology
- Vol. 48 (11) , 1212
Circulating Y-RNAs as New Players in Parkinson Disease and Their Associations with Clinical Measures
Background: Parkinson’s disease (PD) is a progressive neurodegenerative disorder characterized by dopaminergic neuron loss, and current therapies provide only symptomatic relief. Extracellular vesicles (EVs) have emerged as potential mediators of disease-modifying effects through the transfer of proteins, lipids, and non-coding RNAs. Y-RNAs, a conserved yet understudied class of small non-coding RNAs enriched in EVs, are implicated in fundamental cellular processes such as DNA replication, RNA stability, RNA quality control, and stress-response pathways, and may reflect disease-related cellular states, particularly given that some Y-RNA species are primate-specific. This study aimed to characterize Y-RNA expression in human neural cell models, determine how intracellular levels relate to EV-enriched extracellular profiles, and assess whether serum EV-enriched Y-RNAs show PD-associated alterations with diagnostic relevance and associations with clinical status. Methods: Human neural stem cells and malignant neural cell models were profiled for intracellular Y-RNA expression and EV-enriched extracellular Y-RNAs using EV-enriched RNA preparations. Serum samples from individuals with PD and healthy controls were analyzed to quantify circulating EV-enriched Y-RNAs. Relative Y-RNA abundance and pairwise relative Y-RNA expression measures were compared across cellular models, EV-enriched fractions, and clinical samples to identify disease-related patterns. Results: Y-RNAs displayed distinct relative expression patterns across neural cell models. EV-enriched profiles differed markedly from intracellular abundance, with consistent enrichment of RNY4 and depletion of RNY1 in EV-enriched fractions. These intracellular–extracellular differences were preserved in vesicles released under baseline conditions. In serum EV-enriched fractions, PD was associated with a specific Y-RNA signature: RNY3 related to disease presence, whereas RNY5 correlated with disease duration and severity. Pairwise relative Y-RNA expression measures also provided biologically informative signals both in cell models and patient samples. Conclusions: EV-enriched Y-RNA profiles diverge from intracellular patterns and h exploratory clinical relevance in PD, supporting their potential as markers of disease severity and contributors to disease-related molecular communication.
- 13 November 2026
- Published by MDPI AG in Current Issues in Molecular Biology
- Vol. 48 (11) , 1212
Open AccessCirculating Y-RNAs as New Players in Parkinson Disease and Their Associations with Clinical Measures
Background: Parkinson’s disease (PD) is a progressive neurodegenerative disorder characterized by dopaminergic neuron loss, and current therapies provide only symptomatic relief. Extracellular vesicles (EVs) have emerged as potential mediators of disease-modifying effects through the transfer of proteins, lipids, and non-coding RNAs. Y-RNAs, a conserved yet understudied class of small non-coding RNAs enriched in EVs, are implicated in fundamental cellular processes such as DNA replication, RNA stability, RNA quality control, and stress-response pathways, and may reflect disease-related cellular states, particularly given that some Y-RNA species are primate-specific. This study aimed to characterize Y-RNA expression in human neural cell models, determine how intracellular levels relate to EV-enriched extracellular profiles, and assess whether serum EV-enriched Y-RNAs show PD-associated alterations with diagnostic relevance and associations with clinical status. Methods: Human neural stem cells and malignant neural cell models were profiled for intracellular Y-RNA expression and EV-enriched extracellular Y-RNAs using EV-enriched RNA preparations. Serum samples from individuals with PD and healthy controls were analyzed to quantify circulating EV-enriched Y-RNAs. Relative Y-RNA abundance and pairwise relative Y-RNA expression measures were compared across cellular models, EV-enriched fractions, and clinical samples to identify disease-related patterns. Results: Y-RNAs displayed distinct relative expression patterns across neural cell models. EV-enriched profiles differed markedly from intracellular abundance, with consistent enrichment of RNY4 and depletion of RNY1 in EV-enriched fractions. These intracellular–extracellular differences were preserved in vesicles released under baseline conditions. In serum EV-enriched fractions, PD was associated with a specific Y-RNA signature: RNY3 related to disease presence, whereas RNY5 correlated with disease duration and severity. Pairwise relative Y-RNA expression measures also provided biologically informative signals both in cell models and patient samples. Conclusions: EV-enriched Y-RNA profiles diverge from intracellular patterns and h exploratory clinical relevance in PD, supporting their potential as markers of disease severity and contributors to disease-related molecular communication.
- Open Access
- 4 November 2026
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 27 (21) , 9873
Cross-System miRNA Profiling Identifies a Clinically Recurrent miRNA Core in Colorectal Cancer
Colorectal cancer (CRC) encompasses biologically diverse cellular phenotypes with distinct microRNA (miRNA) expression patterns. Assessing whether cell-model-derived alterations recur in extracellular vesicles (EVs) and human tumors may help prioritize candidates with broader relevance to CRC. We performed small RNA sequencing of non-malignant HCoEpiC cells, differentiated enterocyte-like Caco-2 cells, less differentiated HCT116 cells, and their corresponding EVs. miRNAs showing concordant dysregulation in both CRC cell lines relative to HCoEpiC, with greater absolute log2 fold changes in HCT116, were prioritized and evaluated in human colorectal tissues and TCGA-COAD/READ. Seven of 29 prioritized cellular miRNAs met the EV selection criteria. Of the 26 candidates measurable in the patient-tissue dataset, eight showed FDR-significant, directionally concordant differences between CRC and healthy colorectal tissues, including five concordantly dysregulated across cells, EVs, and patient tissues. Analysis of 11 matched TCGA tumor–non-tumor pairs reproduced reduced miR-30a-3p, miR-30c-2-3p, and miR-1271-5p and increased miR-140-5p expression. Target-based enrichment and exploratory miRNA-mRNA correlation analyses identified associations with CRC-relevant signaling and MYC-related, cell-cycle, DNA-repair, and metabolic programs. No significant associations with the evaluated clinicopathological features or overall survival were detected. Collectively, these findings identify a reproducible subset of CRC-associated miRNA alterations and highlight reduced miR-30a-3p and miR-30c-2-3p expression as a recurrent family-level pattern warranting mechanistic investigation.
- 4 November 2026
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 27 (21) , 9873
Open AccessCross-System miRNA Profiling Identifies a Clinically Recurrent miRNA Core in Colorectal Cancer
Colorectal cancer (CRC) encompasses biologically diverse cellular phenotypes with distinct microRNA (miRNA) expression patterns. Assessing whether cell-model-derived alterations recur in extracellular vesicles (EVs) and human tumors may help prioritize candidates with broader relevance to CRC. We performed small RNA sequencing of non-malignant HCoEpiC cells, differentiated enterocyte-like Caco-2 cells, less differentiated HCT116 cells, and their corresponding EVs. miRNAs showing concordant dysregulation in both CRC cell lines relative to HCoEpiC, with greater absolute log2 fold changes in HCT116, were prioritized and evaluated in human colorectal tissues and TCGA-COAD/READ. Seven of 29 prioritized cellular miRNAs met the EV selection criteria. Of the 26 candidates measurable in the patient-tissue dataset, eight showed FDR-significant, directionally concordant differences between CRC and healthy colorectal tissues, including five concordantly dysregulated across cells, EVs, and patient tissues. Analysis of 11 matched TCGA tumor–non-tumor pairs reproduced reduced miR-30a-3p, miR-30c-2-3p, and miR-1271-5p and increased miR-140-5p expression. Target-based enrichment and exploratory miRNA-mRNA correlation analyses identified associations with CRC-relevant signaling and MYC-related, cell-cycle, DNA-repair, and metabolic programs. No significant associations with the evaluated clinicopathological features or overall survival were detected. Collectively, these findings identify a reproducible subset of CRC-associated miRNA alterations and highlight reduced miR-30a-3p and miR-30c-2-3p expression as a recurrent family-level pattern warranting mechanistic investigation.
- Open Access
LDN-27219 Modulates High-Glucose-Induced Endothelial Bioenergetic Remodeling and MitoSOX Red Fluorescence
Background: Endothelial dysfunction is a key feature of diabetic vascular disease and is associated with high-glucose-induced changes in endothelial energy metabolism and redox balance. Transglutaminase-2 has been implicated in vascular stress responses, but its contribution to endothelial adaptation to high glucose remains incompletely defined. Methods: EA.hy926 endothelial cells were cultured under normoglycaemic (NG) or high-glucose conditions and treated with LDN-27219 at 20 µg/mL (48.9 µM). Cellular reducing capacity, total protein content, mitochondrial respiration, MitoSOX Red fluorescence, and selected cytokine and adhesion-marker secretion were assessed. Results: High glucose shifted cells toward a more glycolytic basal phenotype, increased MitoSOX Red fluorescence, and reduced glycolytic stress responsiveness compared with NG conditions. LDN-27219 had limited effects under NG conditions but, under high-glucose conditions, reduced basal respiration, maximal respiration, ATP-linked oxygen consumption, and spare respiratory capacity, while partially restoring stressed extracellular acidification. LDN-27219 also reduced high-glucose-induced MitoSOX Red fluorescence, although this cannot be interpreted as definitive evidence of reduced mitochondrial superoxide production because mitochondrial membrane potential was not measured. No statistically significant changes were detected in the selected inflammatory or adhesion markers. Conclusions: LDN-27219 modifies endothelial bioenergetic and oxidant-associated fluorescence responses under high-glucose conditions.
Open AccessLDN-27219 Modulates High-Glucose-Induced Endothelial Bioenergetic Remodeling and MitoSOX Red Fluorescence
Background: Endothelial dysfunction is a key feature of diabetic vascular disease and is associated with high-glucose-induced changes in endothelial energy metabolism and redox balance. Transglutaminase-2 has been implicated in vascular stress responses, but its contribution to endothelial adaptation to high glucose remains incompletely defined. Methods: EA.hy926 endothelial cells were cultured under normoglycaemic (NG) or high-glucose conditions and treated with LDN-27219 at 20 µg/mL (48.9 µM). Cellular reducing capacity, total protein content, mitochondrial respiration, MitoSOX Red fluorescence, and selected cytokine and adhesion-marker secretion were assessed. Results: High glucose shifted cells toward a more glycolytic basal phenotype, increased MitoSOX Red fluorescence, and reduced glycolytic stress responsiveness compared with NG conditions. LDN-27219 had limited effects under NG conditions but, under high-glucose conditions, reduced basal respiration, maximal respiration, ATP-linked oxygen consumption, and spare respiratory capacity, while partially restoring stressed extracellular acidification. LDN-27219 also reduced high-glucose-induced MitoSOX Red fluorescence, although this cannot be interpreted as definitive evidence of reduced mitochondrial superoxide production because mitochondrial membrane potential was not measured. No statistically significant changes were detected in the selected inflammatory or adhesion markers. Conclusions: LDN-27219 modifies endothelial bioenergetic and oxidant-associated fluorescence responses under high-glucose conditions.
- Open Access
- 7 May 2024
- Published by MDPI AG in Horticulturae
- Vol. 10 (5) , 477
The Impact of Genotype and Controlled Environment Cultivation Parameters on Tomato-Leaf-Derived Exosome-like Nanoparticle Yield and Properties
Horticultural plant material offers several advantages for isolating exosomes and other natural plant-derived exosome-like nanoparticles (PDENs) due to the accessibility and affordability of plant material for widespread applications. This study aims to explore the impacts of the tomato genotype (‘Admiro’, ‘Roma’, ‘Brooklyn’, ‘Marmande’ and ‘Betalux’) and the main cultivation parameters in controlled environment agriculture on the yield and properties of their PDENs for pharmaceutical and cosmeceutical applications. The PDEN yield, size distribution, and antioxidative properties of young tomato seedlings were evaluated. The ‘Betalux’ tomato was distinguished by a remarkably higher nanoparticle concentration and a uniform size distribution and was selected for further experiments. The impact of cultivation temperature (18, 22, and 26 °C), nitrogen nutrition (0, 250, and 500 mg L−1), and the lighting photosynthetic photon flux density (PPFD; 150, 250, and 450 µmol m−2 s−1) on nanoparticle properties was investigated. Optimal conditions consisting of a temperature of 22 °C, 250 mg L−1 nitrogen nutrition, and 250 µmol m−2 s−1 lighting PPFD were used as a reference. Optimal temperature, nitrogen nutrition, and lighting intensity resulted in the highest nanoparticle yield, the most uniform particle distribution, and the highest impact of PDEN preparations on keratinocyte metabolic activity. Deviation from optimal cultivation conditions reduced the tomato biomass and the PDEN protein and yield.
- 7 May 2024
- Published by MDPI AG in Horticulturae
- Vol. 10 (5) , 477
Open AccessThe Impact of Genotype and Controlled Environment Cultivation Parameters on Tomato-Leaf-Derived Exosome-like Nanoparticle Yield and Properties
Horticultural plant material offers several advantages for isolating exosomes and other natural plant-derived exosome-like nanoparticles (PDENs) due to the accessibility and affordability of plant material for widespread applications. This study aims to explore the impacts of the tomato genotype (‘Admiro’, ‘Roma’, ‘Brooklyn’, ‘Marmande’ and ‘Betalux’) and the main cultivation parameters in controlled environment agriculture on the yield and properties of their PDENs for pharmaceutical and cosmeceutical applications. The PDEN yield, size distribution, and antioxidative properties of young tomato seedlings were evaluated. The ‘Betalux’ tomato was distinguished by a remarkably higher nanoparticle concentration and a uniform size distribution and was selected for further experiments. The impact of cultivation temperature (18, 22, and 26 °C), nitrogen nutrition (0, 250, and 500 mg L−1), and the lighting photosynthetic photon flux density (PPFD; 150, 250, and 450 µmol m−2 s−1) on nanoparticle properties was investigated. Optimal conditions consisting of a temperature of 22 °C, 250 mg L−1 nitrogen nutrition, and 250 µmol m−2 s−1 lighting PPFD were used as a reference. Optimal temperature, nitrogen nutrition, and lighting intensity resulted in the highest nanoparticle yield, the most uniform particle distribution, and the highest impact of PDEN preparations on keratinocyte metabolic activity. Deviation from optimal cultivation conditions reduced the tomato biomass and the PDEN protein and yield.
- Open Access
- 10 March 2024
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 25 (6) , 3188
Differential Mitochondrial, Oxidative Stress and Inflammatory Responses to SARS-CoV-2 Spike Protein Receptor Binding Domain in Human Lung Microvascular, Coronary Artery Endothelial and Bronchial Epithelial Cells
Recent evidence indicates that the SARS-CoV-2 spike protein affects mitochondria with a cell type-dependent outcome. We elucidate the effect of the SARS-CoV-2 receptor binding domain (RBD) on the mitochondrial network and cristae morphology, oxygen consumption, mitoROS production, and inflammatory cytokine expression in cultured human lung microvascular (HLMVECs), coronary artery endothelial (HCAECs), and bronchial epithelial cells (HBECs). Live Mito Orange staining, STED microscopy, and Fiji MiNa analysis were used for mitochondrial cristae and network morphometry; an Agilent XFp analyser for mitochondrial/glycolytic activity; MitoSOX fluorescence for mitochondrial ROS; and qRT-PCR plus Luminex for cytokines. HLMVEC exposure to SARS-CoV-2 RBD resulted in the fragmentation of the mitochondrial network, mitochondrial swelling, increased cristae area, reduced cristae density, and suppressed mitochondrial oxygen consumption and glycolysis. No significant mitochondrial morphology or oxygen consumption changes were observed in HCAECs and HBECs. SARS-CoV-2 RBD induced mitoROS-mediated expression of cytokines GM-CSF and IL-1β in all three investigated cell types, along with IL-8 expression in both endothelial cell types. The findings suggest mitochondrial ROS control SARS-CoV-2 RBD-induced inflammation in HLMVECs, HCAECs, and HBECs, with the mitochondria of HLMVECs being more sensitive to SARS-CoV-2 RBD.
- 10 March 2024
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 25 (6) , 3188
Open AccessDifferential Mitochondrial, Oxidative Stress and Inflammatory Responses to SARS-CoV-2 Spike Protein Receptor Binding Domain in Human Lung Microvascular, Coronary Artery Endothelial and Bronchial Epithelial Cells
Recent evidence indicates that the SARS-CoV-2 spike protein affects mitochondria with a cell type-dependent outcome. We elucidate the effect of the SARS-CoV-2 receptor binding domain (RBD) on the mitochondrial network and cristae morphology, oxygen consumption, mitoROS production, and inflammatory cytokine expression in cultured human lung microvascular (HLMVECs), coronary artery endothelial (HCAECs), and bronchial epithelial cells (HBECs). Live Mito Orange staining, STED microscopy, and Fiji MiNa analysis were used for mitochondrial cristae and network morphometry; an Agilent XFp analyser for mitochondrial/glycolytic activity; MitoSOX fluorescence for mitochondrial ROS; and qRT-PCR plus Luminex for cytokines. HLMVEC exposure to SARS-CoV-2 RBD resulted in the fragmentation of the mitochondrial network, mitochondrial swelling, increased cristae area, reduced cristae density, and suppressed mitochondrial oxygen consumption and glycolysis. No significant mitochondrial morphology or oxygen consumption changes were observed in HCAECs and HBECs. SARS-CoV-2 RBD induced mitoROS-mediated expression of cytokines GM-CSF and IL-1β in all three investigated cell types, along with IL-8 expression in both endothelial cell types. The findings suggest mitochondrial ROS control SARS-CoV-2 RBD-induced inflammation in HLMVECs, HCAECs, and HBECs, with the mitochondria of HLMVECs being more sensitive to SARS-CoV-2 RBD.
- Open Access
Assessing the Therapeutic Impacts of HAMLET and FOLFOX on BRAF-Mutated Colorectal Cancer: A Study of Cancer Cell Survival and Mitochondrial Dynamics In Vitro and Ex Vivo
Background and Objectives: Colorectal cancer (CRC) is a major global health challenge. The BRAF V600E mutation, found in 8–12% of CRC patients, exacerbates this by conferring poor prognosis and resistance to therapy. Our study focuses on the efficacy of the HAMLET complex, a molecular substance derived from human breast milk, on CRC cell lines and ex vivo biopsies harboring this mutation, given its previously observed selective toxicity to cancer cells. Materials and Methods: we explored the effects of combining HAMLET with the FOLFOX chemotherapy regimen on CRC cell lines and ex vivo models. Key assessments included cell viability, apoptosis/necrosis induction, and mitochondrial function, aiming to understand the mutation-specific resistance or other cellular response mechanisms. Results: HAMLET and FOLFOX alone decreased viability in CRC explants, irrespective of the BRAF mutation status. Notably, their combination yielded a marked decrease in viability, particularly in the BRAF wild-type samples, suggesting a synergistic effect. While HAMLET showed a modest inhibitory effect on mitochondrial respiration across both mutant and wild-type samples, the response varied depending on the mutation status. Significant differences emerged in the responses of the HT-29 and WiDr cell lines to HAMLET, with WiDr cells showing greater resistance, pointing to factors beyond genetic mutations influencing drug responses. A slight synergy between HAMLET and FOLFOX was observed in WiDr cells, independent of the BRAF mutation. The bioenergetic analysis highlighted differences in mitochondrial respiration between HT-29 and WiDr cells, suggesting that bioenergetic profiles could be key in determining cellular responses to HAMLET. Conclusions: We highlight the potential of HAMLET and FOLFOX as a combined therapeutic approach in BRAF wild-type CRC, significantly reducing cancer cell viability. The varied responses in CRC cell lines, especially regarding bioenergetic and mitochondrial factors, emphasize the need for a comprehensive approach considering both genetic and metabolic aspects in CRC treatment strategies.
Open AccessAssessing the Therapeutic Impacts of HAMLET and FOLFOX on BRAF-Mutated Colorectal Cancer: A Study of Cancer Cell Survival and Mitochondrial Dynamics In Vitro and Ex Vivo
Background and Objectives: Colorectal cancer (CRC) is a major global health challenge. The BRAF V600E mutation, found in 8–12% of CRC patients, exacerbates this by conferring poor prognosis and resistance to therapy. Our study focuses on the efficacy of the HAMLET complex, a molecular substance derived from human breast milk, on CRC cell lines and ex vivo biopsies harboring this mutation, given its previously observed selective toxicity to cancer cells. Materials and Methods: we explored the effects of combining HAMLET with the FOLFOX chemotherapy regimen on CRC cell lines and ex vivo models. Key assessments included cell viability, apoptosis/necrosis induction, and mitochondrial function, aiming to understand the mutation-specific resistance or other cellular response mechanisms. Results: HAMLET and FOLFOX alone decreased viability in CRC explants, irrespective of the BRAF mutation status. Notably, their combination yielded a marked decrease in viability, particularly in the BRAF wild-type samples, suggesting a synergistic effect. While HAMLET showed a modest inhibitory effect on mitochondrial respiration across both mutant and wild-type samples, the response varied depending on the mutation status. Significant differences emerged in the responses of the HT-29 and WiDr cell lines to HAMLET, with WiDr cells showing greater resistance, pointing to factors beyond genetic mutations influencing drug responses. A slight synergy between HAMLET and FOLFOX was observed in WiDr cells, independent of the BRAF mutation. The bioenergetic analysis highlighted differences in mitochondrial respiration between HT-29 and WiDr cells, suggesting that bioenergetic profiles could be key in determining cellular responses to HAMLET. Conclusions: We highlight the potential of HAMLET and FOLFOX as a combined therapeutic approach in BRAF wild-type CRC, significantly reducing cancer cell viability. The varied responses in CRC cell lines, especially regarding bioenergetic and mitochondrial factors, emphasize the need for a comprehensive approach considering both genetic and metabolic aspects in CRC treatment strategies.
- Open Access
- 21 November 2023
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 24 (23) , 16554
The Effect of SARS-CoV-2 Spike Protein RBD-Epitope on Immunometabolic State and Functional Performance of Cultured Primary Cardiomyocytes Subjected to Hypoxia and Reoxygenation
Cardio complications such as arrhythmias and myocardial damage are common in COVID-19 patients. SARS-CoV-2 interacts with the cardiovascular system primarily via the ACE2 receptor. Cardiomyocyte damage in SARS-CoV-2 infection may stem from inflammation, hypoxia–reoxygenation injury, and direct toxicity; however, the precise mechanisms are unclear. In this study, we simulated hypoxia–reoxygenation conditions commonly seen in SARS-CoV-2-infected patients and studied the impact of the SARS-CoV-2 spike protein RBD-epitope on primary rat cardiomyocytes to gain insight into the potential mechanisms underlying COVID-19-related cardiac complications. Cell metabolic activity was evaluated with PrestoBlueTM. Gene expression of proinflammatory markers was measured by qRT-PCR and their secretion was quantified by Luminex assay. Cardiomyocyte contractility was analysed using the Myocyter plugin of ImageJ. Mitochondrial respiration was determined through Seahorse Mito Stress Test. In hypoxia–reoxygenation conditions, treatment of the SARS-CoV-2 spike RBD-epitope reduced the metabolic activity of primary cardiomyocytes, upregulated Il1β and Cxcl1 expression, and elevated GM-CSF and CCL2 cytokines secretion. Contraction time increased, while amplitude and beating frequency decreased. Acute treatment with a virus RBD-epitope inhibited mitochondrial respiration and lowered ATP production. Under ischaemia-reperfusion, the SARS-CoV-2 RBD-epitope induces cardiomyocyte injury linked to impaired mitochondrial activity.
- 21 November 2023
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 24 (23) , 16554
Open AccessThe Effect of SARS-CoV-2 Spike Protein RBD-Epitope on Immunometabolic State and Functional Performance of Cultured Primary Cardiomyocytes Subjected to Hypoxia and Reoxygenation
Cardio complications such as arrhythmias and myocardial damage are common in COVID-19 patients. SARS-CoV-2 interacts with the cardiovascular system primarily via the ACE2 receptor. Cardiomyocyte damage in SARS-CoV-2 infection may stem from inflammation, hypoxia–reoxygenation injury, and direct toxicity; however, the precise mechanisms are unclear. In this study, we simulated hypoxia–reoxygenation conditions commonly seen in SARS-CoV-2-infected patients and studied the impact of the SARS-CoV-2 spike protein RBD-epitope on primary rat cardiomyocytes to gain insight into the potential mechanisms underlying COVID-19-related cardiac complications. Cell metabolic activity was evaluated with PrestoBlueTM. Gene expression of proinflammatory markers was measured by qRT-PCR and their secretion was quantified by Luminex assay. Cardiomyocyte contractility was analysed using the Myocyter plugin of ImageJ. Mitochondrial respiration was determined through Seahorse Mito Stress Test. In hypoxia–reoxygenation conditions, treatment of the SARS-CoV-2 spike RBD-epitope reduced the metabolic activity of primary cardiomyocytes, upregulated Il1β and Cxcl1 expression, and elevated GM-CSF and CCL2 cytokines secretion. Contraction time increased, while amplitude and beating frequency decreased. Acute treatment with a virus RBD-epitope inhibited mitochondrial respiration and lowered ATP production. Under ischaemia-reperfusion, the SARS-CoV-2 RBD-epitope induces cardiomyocyte injury linked to impaired mitochondrial activity.